Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation by Ibrahim, Ahmed S. et al.
Genistein attenuates retinal inflammation associated with diabetes
by targeting of microglial activation
Ahmed S. Ibrahim,1,3 Mamdouh M. El-Shishtawy,3 Alejandro Peña Jr.,2 Gregory I. Liou1
1Department of Ophthalmology, Medical College of Georgia, Augusta, GA; 2Department of Medicine, Medical College of Georgia,
Augusta, GA; 3Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt
Purpose: Diabetic retinopathy (DR) is associated with microglial activation and increased levels of inflammatory
cytokines. Genistein, a tyrosine kinase inhibitor, has been shown to possess anti-inflammatory potential that so far untested
in animal models of diabetes. The aims of this study are to evaluate the efficacy of genistein for alleviation of diabetes-
induced retinal inflammation and also to gain insight into the molecular mechanisms involved therein by analyzing the
effect of genistein on concomitant microglia activation in the diabetic retina and in isolated cells.
Methods: Streptozotocin (STZ)-induced diabetic Sprague Dawley rats were used. After diabetes was established for two
weeks a single intravitreal injection of genistein or vehicle was performed. Forty-eight hours later, rats were killed, their
retinal  and  vitreal  samples  were  processed  for  Quantitative  Real  Time-PCR  (qRT–PCR)  and  Enzyme-linked
immunosorbent assay (ELISA) analyses, respectively. For the in vitro study, isolated microglial cells from retinas of
newborn rats were used.
Results: mRNA as well as protein levels for tumor necrosis factor α (TNF-α), a robust marker of inflammation, were
increased in the retina early in the course of diabetes. Moreover, diabetes resulted in elevation of ionized calcium binding
adaptor molecule-1 (Iba1) mRNA, known to be upregulated in activated microglia. These effects of diabetes in retina
were all reduced by intervention treatment with genistein. Using an in vitro bioassay, we demonstrated the release of TNF-
α from microglia activated by glycated albumin, a risk factor for diabetic disorders. This inflammatory signal involves
the activation of tyrosine kinase and its subsequent events, ERK and P38 MAPKs. Genistein represses the release of TNF-
α and significantly inhibits ERK and P38 phosphorylation in activated microglial cells by acting as a tyrosine kinase
inhibitor.
Conclusions: These findings show genistein to be effective in dampening diabetes-induced retinal inflammation by
interfering with inflammatory signaling (ERK and P38 MAPKs) that occurs in activated microglia. This beneficial effect
of genistein may represent a new intervention therapy to modulate early pathological pathways long before the occurrence
of vision loss among diabetics.
Diabetes is a global health problem and its prevalence is
set to increase up to 366 million worldwide by the year 2030
[1].  Persistent  hyperglycemia  in  diabetic  patients  despite
appropriate  therapeutic  measures  leads  to  several
complications  including  retinopathy,  nephropathy,  and
neuropathy. Diabetic retinopathy (DR) is the most prevalent
microvascular complication affecting approximately 50% of
diabetic patients within 15 years after onset of the disease
[2]. Complications from the condition may include gradual
loss of sharpness of vision, and at their most extreme, total
loss. Laser treatment which has been a standard therapy for
the past 25 years, does not prevent DR nor is it used to treat
mild or moderate DR, rather it is used to treat only serious,
vision threatening DR. Therefore, there is a great need for the
development of new and effective therapies for treating DR
early before it causes irreparable damage to the retina.
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The  etiology  of  diabetic  retinopathy  is  complex  and
multi-factorial. During the past decade, it has been suggested
that  inflammation,  induced  by  hyperglycemia  or  glycated
proteins, is a central contributing factor in pathogenesis of
diabetic retinopathy [3]. Clinical studies have shown elevated
levels of pro-inflammatory cytokines in the vitreous fluid of
patients with diabetic retinopathy, which are related with the
activity and progression of retinal injury [4]. Experimental
animal investigations have shown that mRNA expression for
TNF-α, a robust marker of inflammation, is increased in the
retina early in the course of diabetes, and moreover, inhibition
of  TNF-α  has  demonstrated  beneficial  effects  in  the
prevention of early diabetic retinopathy [5].
Cellular sources of these inflammatory mediators include
infiltrated leukocytes and the pre-stationed glial-immune cells
known as-microglia. The importance of retinal microglia as
responders  to  hyperglycemic  stress  has  recently  been
emphasized in experimental diabetes. In vitro cellular models,
activation of microglia cells with glycated albumin or high
glucose has been used as a model to simulate inflammation
during diabetes [6]. In a diabetic animal model, streptozotocin
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2033(STZ)-induced  diabetic  rats  have  been  shown  to  develop
retinal microglia activation leading to the release of soluble
cytotoxins that contribute to neuronal and vascular cell death
and  ultimately  the  progression  of  DR  [7].  As  such,
pharmacologic regulation of microglial activity is therefore a
rational approach to modulate early pathological pathways
associated with DR long before the occurrence of vision loss
among diabetics.
Genistein,  an  isoflavonoid,  is  a  naturally  occurring
tyrosine  kinase  inhibitor  that  has  recently  attracted
considerable attention, as it has a wide therapeutic index [8]
and it is effective in several animal models in which microglia
and inflammation have been implicated. Genistein protects
dopaminergic  neurons  from  lipopolysaccharide-induced
injury by inhibiting microglial activation [9]. It also has been
shown  that  genistein  reduces  pro-inflammatory  factor-
induced vascular endothelial barrier dysfunction and inhibits
leukocyte-endothelium interaction, the major events in the
pathogenesis of atherosclerosis [10]. Moreover, it has proven
that genistein protects neurons from transient global cerebral
ischemia/reperfusion  injury  in  rat  hippocampus  [11].
However, the effects of genistein on retinal inflammation and
microglia activation during diabetes have not been reported.
The present study evaluates the ability of intravitreal genistein
to  attenuate  diabetes-induced  retinal  inflammation.
Furthermore,  this  study  pursues  to  gain  insight  into  the
mechanistic basis behind this effect. Because genistein has an
attractive safety profile and appreciable anti-inflammatory
activity, it may represent a potential therapeutic agent for
managing retinal complications during diabetes.
METHODS
Materials:  Genistein  was  purchased  from  LC  laboratory
(Woburn,  MA).  Antibodies  against  glial  fibrillar  acidic
protein (GFAP), phospho-tyrosine, phospho-ERK (pERK),
ERK, phospho-P38 (pP38) and P38 were purchased from Cell
Signaling  (Beverly,  MA).  Anti-Iba1  was  purchased  from
Wako  (Richmond,  VA).  Anti-glycated  albumin  antibody
(A717) was purchased from Exocell (Philadelphia, PA). P38
inhibitor,  SB203580,  was  purchased  from  Calbiochem
(Gibbstown, NJ). β-actin antibody, ERK inhibitor (U0126),
glycated  and  nonglycated  albumin  were  purchased  from
Sigma (St. Louis, MO). Glycated albumin contained 3 mol of
fructoselysine per mol albumin. The absence of advanced
glycation end products (AGE) in the glycated albumin was
assessed  by  measuring  of  AGE-related  fluorescence  at
excitation maximum of 370 nm and emission maximum of
440  nm  as  described  previously  [12].  Endotoxin  was  not
detectable in the glycated or nonglycated albumin by the use
of Limulus Amebocyte Lysate test kit.
Animal preparation and experimental design: All procedures
with animals were performed in accordance with the Public
Health Service Guide for the Care and Use of Laboratory
Animals  (Department  of  Health,  Education,  and  Welfare
publication,  NIH  80–23),  Medical  College  of  Georgia
guidelines and The Association for Research in Vision and
Ophthalmology  Statement  for  the  Use  of  Animals  in
Ophthalmic and Vision Research. Diabetes was induced for
2-weeks in male Sprague-Dawley (SD) rats (bodyweight, 200
g) by intravenous injection of STZ (60 mg/kg) in sodium
citrate. Detection of glucose in the urine and blood glucose
levels >250 mg/dl were the markers to indicate diabetic status.
The diabetic rats were randomly divided into two subgroups:
genistein-treated and vehicle-treated subgroups.
Intravitreal  injection:  This  procedure  was  essentially  the
same as previously described [13]. To avoid uncontrolled
intraocular  pressure  increase,  the  volume  of  intravitreal
injections was limited to 2 µl. Genistein was dissolved in
dimethyl sulfoxide (DMSO) and a working solution of 25x
was prepared by diluting 1.25 µl of stock solution (100 mM)
to 100 µl with phosphate-buffered saline (PBS), assuming the
vitreous volume of rat eye is 50 µl [14]. Then by injecting
2 μl of this working solution, 50 µM vitreal concentration of
genistein was obtained. The vitreal concentration of DMSO
(DMSO) was 0.05%. To ensure the proper delivery and even
distribution  of  the  intravitreally  injected  compounds,  all
solutions for intravitreal injection contained 5 µg/ml of Fast
Green  FCF  (Sigma,  St.  Louis,  MO).  The  volume  of  the
injected  solution  apparently  did  not  cause  significant
pressure-induced  retinal  damage,  because  PBS-injected
control  eyes  showed  normal  retinal  morphology  with  no
apparent apoptosis within 7 days. Intravitreal injections were
performed in 2-weeks diabetic rats. 48 h later, rats were killed,
and their retinal as well as vitreal samples were collected
separately. The retinas were removed, snap frozen in liquid
nitrogen, stored at −80 °C, and analyzed by Quantitative Real
Time-PCR  (qRT–PCR)  or  western  blot,  while  the  vitreal
samples were centrifuged and used for the measurement of
TNF-α release by ELISA. (n=6 per group).
Primary  retinal  microglia  culture:  Microglial  cells  were
isolated from retinas of newborn Sprague Dawley (SD) rats
according  to  a  previous  procedure  [15],  with  minor
Modifications. Briefly, retinas were collected into 0.01 M
PBS and digested with 0.125% trypsin for 3–5 min before
mixing with Dulbecco’s Modified Eagle Medium (DMEM)/
F12  containing  10%  fetal  bovine  serum  (FBS)  and  1%
penicillin/streptomycin.  Retina  pieces  were  then  filtered
through  a  mesh  (100  µm),  collected  by  centrifugation,
resuspended in culture medium and plated onto T150 cell
culture flasks (Corning, NY) at a density of 2×105 cells/cm2.
After 2 weeks, microglial cells were harvested by shaking the
flasks  at  100  rpm  for  1  h.  Immunocytochemical  studies
showed that more than 95% cultured cells stained positively
for Iba1. Almost none of these cells showed positive staining
for GFAP, indicating that majority of the isolated cells were
microglia  and  were  not  contaminated  with  astrocytes  or
Müller  cells  (data  not  shown).  For  microglia  activation,
glycated albumin was added to each well in Cellgro Complete
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a control. The final concentrations of drugs were: genistein,
(10–100  µM);  U0126,  10  µM;  SB  203580,  10  µM.  Cell
viability was determined by counting the number of trypan
blue–excluding cells under an inverted microscope, using a
hemocytometer. Cells were homogenized for western blot
analysis.  Culture  media  were  used  for  TNF-α  release
determination by ELISA.
Quantitative Real Time-PCR: Total RNA was isolated from
rat retina using Promega SV Total RNA Isolation System.
Subsequently, cDNAs were generated from 1 μg of total RNA
using  High-Capacity  cDNA  Reverse  Transcription  Kit
(Applied Biosystems). The resulting cDNA was subjected to
a 40 cycle PCR amplification using manufacturer’s TaqMan
Universal  PCR  Master  Mix  protocol.  Quantification  of
Iba-1,  TNF-α,  and  Glyceraldehyde-3-phosphate
dehydrogenase  (GAPDH)  transcripts  were  performed  by
relative  quantitative  real-time  RT–PCR  with  TaqMan®
Probe-based Assays and Applied Biosystems 7300 Sequence
Detection system. The ready-made primer and probe sets were
ordered  from  Applied  Biosystems  (Catalog  #:  Iba-1:
Rn01525935_m1;  TNF-α:  Rn99999017_m1;  GAPDH:
Rn01775763_g1). Three replicates were run for each gene for
each sample in a 96-well plate. GAPDH was used as the
endogenous reference gene as it does not exhibit significant
expression  changes  between  groups  of  samples  (data  not
shown). The relative quantitation method (ΔΔCt) was used,
with the ratio of target mRNA, normalized respect to GAPDH
mRNA and relative to a calibrator sample. PBS-normal, non-
diabetic, retinas were used as calibrators.
Enzyme-linked immunosorbent assay (ELISA) for TNF-α in
vitreous or culture media: TNF-α levels in the samples were
estimated  with  ELISA  (R&D)  per  the  manufacturer’s
instructions. Briefly, standards and samples were bound by
the immobilized antibody, and an enzyme-linked polyclonal
antibody specific for the cytokine was added to the wells
followed by a substrate solution yielding a colored product.
The intensity of the color was measured at 450 nm. The sample
levels  were  calculated  from  a  standard  curve  and  were
corrected for protein concentration.
Immunolocalization of TNF-α and retinal glial cells: Retinal
frozen  sections  (10  µm)  were  prepared  for
immunofluorescence and incubated with the microglial cell-
specific marker anti-Iba-1 together with anti-TNF-α (Santa
Cruz). This was followed by incubation with Texas red- and
Oregon  green-labeled  secondary  antibodies  (Molecular
Probes).  The  same  procedure  was  applied  to  astrocytes/
Mueller cell marker anti-GFAP, together with anti-TNF-α
followed by Texas red- and Oregon green-labeled secondary
antibodies. Slides were examined by confocal microscopy
(LSM  510,  Carl  Zeiss).  Specificity  of  the  reaction  was
confirmed by omitting the primary antibody. Images were
collected from five sections per rat of at least three rats in each
group.
Western  blot  analysis:  Retina  and  cell  homogenates  was
subjected to western blot analysis according to a previous
procedure  [15].  Antibodies  for  β-actin,  glycated  albumin,
phospho-tyrosine, phospho-ERK and ERK, phospho-P38 and
P38 were detected with a horseradish peroxidase-conjugated
antibody and enhanced chemiluminescence detection system
(Amersham BioSciences). Intensity of immunoreactivity was
measured by densitometry.
Data analysis: The results were expressed as mean ± SD.
Differences among experimental groups were evaluated by
ANOVA, and the significance of differences between groups
was  assessed  by  the  posthoc  test  (Fisher’s  PLSD)  when
indicated. Significance was defined as p<0.05.
RESULTS
Genistein attenuates retinal inflammation during diabetes:
Given the inflammatory nature of early diabetic retinopathy
[16] and the fact that the tyrosine kinase signaling cascade
plays  a  pivotal  role  in  initiating  activation  of  various
inflammatory cells [17], we hypothesized that genistein, a
tyrosine kinase inhibitor, may also be effective in attenuation
of diabetes-induced retinal inflammation. To test this, the
effect  of  intravitreal  genistein  on  retinal  TNF-α  mRNA
expression as well as protein levels were determined. In this
study, 2-weeks diabetic rats were treated with genistein or
DMSO intraocularly. After 48 h, TNF-α mRNA expression
was determined by Quantitative Real Time-PCR and vitreal
TNF-α was determined by ELISA. As shown in Figure 1A,B,
intravitreal  injection  of  genistein  resulted  in  significant
inhibition  of  STZ-induced  TNF-α  expression  and  release.
Furthermore, the results of these analyses confirmed previous
reports that inflammation is an early and important component
of diabetic retinopathy [7,18].
Genistein reduces microglial activation in the diabetic retina:
After having shown that genistein exhibits profound reduction
in both TNF-α expression and release, we next sought to
explore a potential mechanism by which genistein regulates
inflammation  in  diabetic  retinopathy.  First,  we  performed
additional studies to identify the main source of TNF-α in the
diabetic retina. Because glial cells (microglia and macroglia)
are the most potential candidates for inflammatory cytokine
production,  we  used  double  labeling  with  specific  glial
markers  (Iba-1  for  activated  microglia  and  GFAP  for
astrocytes or Müller cells) to determine the cellular source of
TNF-α  production.  Through  immunofluorescence,  TNF-α
was colocalized with Iba-1 but not with GFAP, indicating that
microglia are the main cell type producing TNF-α; at least
during the 2-weeks of diabetes (Figure 1C). Next, we aimed
to determine whether the curative effect of genistein was
mediated by targeting of microglial activity. To test this, the
effect of intravitreal genistein on microglial activation was
determined  by  measuring  Iba1  expression,  which  is
upregulated  in  activated  microglia.  To  monitor  microglial
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2035activation, the level of Iba1 mRNA was quantified in retinas
after 48 h of genistein or vehicle treatment. As assessed by
Quantitative Real Time-PCR, whole retina Iba1 mRNA in
genistein-treated  rats  was  approximately  75%  lower  on
average  than  in  vehicle-treated  diabetic  rats  (Figure  1D).
Together, these findings suggest that genistein reduces STZ-
induced retinal inflammation by dampening microglial cell
activation.
Genistein,  a  tyrosine  kinase  inhibitor,  mitigates  TNF-α
release  in  stimulated  retinal  microglial  cells:  From
aforementioned  evidence  that  highlighted  the  anti-
inflammatory potential of genistein by targeting of microglial
activity  in  STZ-injected  rats,  a  cultured  retinal  microglia
model was developed. This cultured model is advantageous
because  it  offers  a  more  detailed  characterization  of
genistein’s anti-inflammatory actions and also helps elucidate
the molecular mechanism responsible for this effect. In this
model, we determined the ability of genistein to affect TNF-
α  release  from  retinal  microglia  in  response  to  glycated
albumin, a risk factor for diabetic disorders. Glycated albumin
was found to be increased in the retina of 2-weeks diabetic
rats (Figure 2A) and has been shown to elicit the inflammatory
response  in  isolated  microglia  cells.  This  inflammatory
response  was  characterized  by  a  dose-dependent  TNF-α
production after 4 h incubation with increasing amounts of
glycated albumin (Figure 2B).
Figure 1. Effect of intravitreally injected genistein on Streptozotocin (STZ)-induced retinal inflammation and microglial activation. 2-weeks
diabetic rats were treated with genistein (50 µM) or vehicle (0.05% DMSO) intraocularly. 48 h later rats were killed and their retinal and
vitreal samples were processed for Quantitative Real Time-PCR (qRT–PCR) and enzyme-linked immunosorbent assay (ELISA) analyses,
respectively, (n=6). A: qRT–PCR analysis for TNF-α expression in diabetic rat retinas after 48 h treatment with genistein or vehicle
intraocularly. The level of gene expression was presented as the mean fold change±SD relative to normal non-diabetic rats. B: ELISA analysis
of vitreal TNF-α release in vitreous and expressed as absolute value±SD C: Representative images show the colocalization of TNF-α with
glial markers in the retina of 2-weeks diabetic rats. Iba-1 (red), a marker of activated microglia; glial fibrillary acidic protein (GFAP; red), a
marker of astrocytes or activated Müller cells. Yellow displayed from merged red and green. Scale bar represents 20 μm. Abbreviations:OPL
indicates outer plexiform layer; GCL indicates ganglion cell layer; (magnification, 200×). D: Effect of intravitreally injected genistein on
microglial activation assayed by Iba1 mRNA expression using qRT–PCR. The level of gene expression was presented as the mean fold change
±SD relative to normal non-diabetic rats.
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2036Of note, the increment of TNF-α level is significantly
measureable  at  4  h  after  glycated  albumin  treatment  and
continued for 24 h (Ibrahim et al. submitted). Moreover, this
early time point was chosen in this study to minimize the
positive feed-back effect of TNF-α [19]. The concentration of
glycated albumin (500 µg/ml) chosen in our study is close to
what has been used previously by several investigators to
study  other  glycated  albumin-mediated  responses  such  as
stimulation  of  glomerular  endothelial  and  mesangial  cell
expression of collagen type IV [20] and represents those found
in clinical specimens. In non diabetic individuals, ~1% of
serum albumin is in the glycated form, which is equivalent to
concentrations of 300–400 µg/ml of glycated albumin. The
concentration of glycated albumin is increased one-and-a-
half- to threefold in diabetic subjects, according to recent
glycemic status [21]. To assess the ability of genistein to
reduce TNF-α release, microglial cells were pretreated with
indicated concentrations of genistein for 1/2 h then stimulated
with  glycated  albumin  for  4  h.  The  supernatants  were
collected and assayed for TNF-α by ELISA. As shown in
Figure  3A,  genistein  inhibited  glycated  albumin-mediated
TNF-α release in a dose-dependent manner. To ensure that
this  effect  was  not  caused  by  nonspecific  cytotoxicity  of
genistein, we assessed cell viability in microglial cells 4 h after
an exposure to genistein, using the trypan blue exclusion test.
As shown in Figure 3B, genistein did not affect cell viability
(88%–94% vital cells), which indicates that the decrease in
TNF-α release was indeed consecutive to genistein’s anti-
inflammatory effect but not to cell death.
To verify that the inhibitory effect of genistein on TNF-
α release from activated microglia was mediated by protein
tyrosine  kinase  inhibition,  we  first  tested  the  potential  of
glycated albumin to induce tyrosine kinase activation. To
address this point, microglial cells were treated with glycated
albumin then at 1/4, 1, and 4 h later cultures were rinsed with
PBS  and  the  cells  were  lysed.  Cell  lysates  were
electrophoresed  on  SDS–PAGE  gels,  electroblotted  onto
nitrocellulose  membranes,  and  probed  with  antibody  to
phosphotyrosine. Tyrosine phosphorylation of many proteins,
determined by western blot, occurred at 15 min and continued
over the 4-h experimental period (Figure 3C). This result
indicates  that  tyrosine  phosphorylation  is  among  the
molecular events induced in microglia after glycated albumin
treatment. Second, we examined the effects of genistein on
glycated albumin-induced protein tyrosine phosphorylation in
retinal microglia. Genistein was added 1/2 h before treatment
with  glycated  albumin  for  1  and  4  h  and  the  tyrosine
phosphorylation profile was determined. Glycated albumin-
induced increases in the level of cellular phosphotyrosine
were suppressed by pretreatment with genistein (Figure 3C).
This result clearly demonstrates the tyrosine kinase inhibitory
effect of genistein. Moreover, the inhibitory effect of genistein
on TNF-α release demonstrates that tyrosine phosphorylation
Figure 2. Accumulation of glycated albumin in diabetic retina and its inflammatory potential for microglia cells. A: Glycated albumin
expression in normal, 2-weeks diabetic rats, and 12.5 ng of glycated albumin product (Sigma), analyzed by western blot using mouse
monoclonal antibody A717. The mean ratio±SD of the intensity of glycated albumin versus actin was indicated below each group. The ratio
of normal, non diabetic rats was taken as 1.0. B: Dose-dependent release of tumor necrosis factor α (TNF-α) in glycated albumin-treated
microglial cells. Microglial cells were stimulated with 10, 50, 200, 500 µg/ml glycated albumin for 4 h. TNF-α levels assayed by enzyme-
linked immunosorbent assay (ELISA) in culture supernatant were compared with corresponding dosage of non-glycated albumin-treated cells
and are expressed as means±SD for three independent experiments.
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TNF-α release from retinal microglial cells.
Genistein  mediates  anti-inflammatory  effect  by  inhibiting
glycated  albumin-dependent  phosphorylation  of  ERK  and
P38 in retinal microglial cells: In light of genistein’s anti-
inflammatory effect, interest in its mechanisms of action has
expanded to include several protein kinase pathways. The
mitogen-activated protein kinase superfamily is composed of
several  signaling  pathways  including  extracellular  signal-
regulated kinase (ERK), c-jun NH2-terminal kinases (JNKs)
and p38 MAPKs. The ERK and p38 MAPKs pathways are the
primary signaling pathways that are activated in microglia
treated  with  glycated  albumin  (Ibrahim  et  al.,  submitted).
Whether or not these kinases are modulated by genistein was
also examined. Microglial cells were pretreated with 100 µM
genistein  for  30  min  and  then  stimulated  with  glycated
albumin for 4 h; phosphorylation of ERK and P38 were then
measured.  Genistein  inhibited  most  of  the  ERK
phosphorylation induced by glycated albumin (Figure 4A). In
addition, genistein significantly reduced glycated albumin-
stimulated  P38  phosphorylation  (Figure  4B).  Further,  we
determined  ERK  and  P38  contribution  to  TNF-α  release.
Microglial cells were pre-treated with U0126 and SB203580
individually or in combination for 30 min and treated with
glycated albumin for 4 h. The combination of ERK and P38
inhibitors  resulted  in  almost  totally  inhibition  of  TNF-α
release  (Figure  4C).  Together,  these  results  suggest  that
genistein  inhibits  glycated  albumin-induced  expression  of
TNF-α through inhibition of ERK and P38 MAPKs. At the
same time, these results indicate that phosphorylated tyrosines
are common signaling molecules that are located upstream of
Figure 3. As a tyrosine kinase inhibitor, genistein mitigates tumor necrosis factor α (TNF-α) release in stimulated retinal microglia cells. A:
Genistein’s dose-dependent inhibition of TNF-α release from activated microglia. Cells were treated with (500 μg/ml) glycated albumin for
4 h in the presence of indicated concentrations of genistein. TNF-α released was analyzed by enzyme-linked immunosorbent assay (ELISA).
Values represent the means percentage±SD of TNF-α release compared with that of glycated albumin-treated in presence of vehicle for three
experiments. B: Genistein also had no effect on cell viability, as determined by trypan blue exclusion test. C: Time-dependent, glycated
albumin-induced tyrosine phosphorylation in microglial cells. Cells were treated with (500 μg/ml) glycated albumin in the presence or absence
of 100 µM genistein for the indicated time. Phosphorylated tyrosine was determined by Western analysis. Intensities of phosphorylated tyrosine
for each time points were compared with the control (time 0). Data shown is the mean±SD of three experiments. * p<0.001 compared with 0
time; $ p<0.001 compared with non-genistein treated, 1 h; # p<0.001 compared with non-genistein treated, 4 h.
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glycated albumin-treated retinal microglial cells.
DISCUSSION
Recent biochemical and neurobiological studies have shown
that retinal glial cell dysfunction and signs of inflammatory
reactions [22], including TNF-α release, are relatively early
events  that  occur  in  response  to  diabetes  before  vascular
dysfunction  involving  acellular  capillary  formation  and
neovascularization [23]. Moreover, TNF-α has been shown to
recruit leukocytes, cause vascular breakdown and promote
neuronal injury at high levels. Thus, treatments targeting early
features  of  diabetic  retinopathy  would  provide  long-term
vascular benefits [16]. The in vitro and in vivo bioassay data
in this study demonstrated the ability of genistein to counteract
retinal  inflammation  during  diabetes  by  dampening  of
microglia activation and TNF-α-release. Genistein has a wide
therapeutic index with very low toxicity [8] and its efficacy
has  been  demonstrated  in  different  animal  models  of
inflammatory diseases.
In relation to diabetes, genistein has shown a plethora of
beneficial effects in experimental animals. Chronic treatment
with  genistein  improved  the  functional  changes  in  aortic
vascular  reactivity  and  inhibited  retinal  vascular  leakage
observed in diabetic rats [24,25]. Recently genistein has been
reported  for  its  potential  hypoglycemic  activity  following
chronic systemic administration. This anti-diabetic effect of
genistein is mediated via preservation of insulin positive β-
cells  and  restoration  of  the  glucose  metabolic  enzyme
activities  independently  from  its  tyrosine  kinase  activity
Figure 4. Genistein inhibits MAPK activation in stimulated microglial cells. A, B: Cells were treated with vehicle or 100 µM of genistein 30
min before (500 μg/ml) glycated albumin treatment for 4 h. Phospho-ERK, total ERK, Phospho-P38, and total P38 MAPK were determined.
Each glycated albumin-treated samples with or without genistein were compared with the untreated sample, set as 1.0. Data shown is the mean
±SD of three experiments. * p<0.001. C: Contribution of ERK and P38 MAPKs to tumor necrosis factor α (TNF-α) release in response to
glycated albumin. Cells were treated with U0126 (10 µM) or with SB203580 (10 µM) either alone or in combination for 30 min. Cells were
then treated with glycated albumin (500 μg/ml) for 4 h. TNF-α levels were compared to the vehicle-treated control. Data shown is the mean
±SD of three experiments.
Molecular Vision 2010; 16:2033-2042 <http://www.molvis.org/molvis/v16/a219> © 2010 Molecular Vision
2039[26]. Because hyperglycemia is known to be responsible for
the  functional  abnormalities  associated  with  diabetes,  any
beneficial effects of genistein might be secondary to its action
on  insulin  secretion  or  hyperglycemia.  However,  the
demonstration  that  genistein  reduces  the  expression  of
proinflammatory cytokines in other diseases has raised the
possibility of anti-inflammatory properties beyond its role as
an anti-diabetic agent. In the context of diabetes, these two
effects of genistein cannot be separated. In this study, we put
forward a new concept pertaining to the therapeutic effect of
genistein  in  treating  diabetic  retinal  inflammation
independently of its anti-diabetic property. To distinguish the
possible retinal anti-inflammatory effects of genistein from its
activity as an insulin releaser, we examined the local ocular
effect  of  genistein  in  STZ-induced  diabetic  animals.  The
intraocular structures of the eye are isolated from the systemic
circulation by both the inner and outer blood–retinal barriers,
these barriers permit local delivery of active drug products
directly  while  minimizing  systemic  absorption  and  side
effects. Therefore, any anti-inflammatory effects of the drug
were  not  secondary  to  its  action  on  insulin  secretion  or
hyperglycemia.
Intravitreal injection of genistein, in the present work,
was found to cause a significant inhibition of TNF-α mRNA
as well as protein levels in diabetic retina, demonstrating the
curative effect of genistein on inflammation associated with
STZ-diabetic model. Moreover, systemic adverse side effects
that might be associated with genistein therapy have been
addressed by using intravitreal injection for the drug. A 50 µM
concentration  (0.675  µg)  of  genistein  was  used  for  the
intravitreal injection in this study. This concentration is well
below the safety range of intravitreal genistein. At a 500-
micromole concentration (0.135 g), genistein did not show
any toxic effects, either on histological or electrophysiological
examination  of  the  retina  [27].  Genistein  also  prevented
retinal microglia from upregulating Iba1 mRNA, supporting
the hypothesis that genistein reduces the retinal inflammation
and inflammatory cytokines expression through attenuation
of microglia activation.
Following this further, we used primary culture of rat
retinal microglial cells to gain insight about the mechanistic
action of genistein’s anti-inflammatory effect. The results of
our experiments indicate that genistein interrupts the glycated
albumin signaling cascade in retinal microglial cells that leads
to secretion of proinflammatory cytokines. Genistein, when
used in 50–100 µM, is a well recognized inhibitor of tyrosine
kinase activity in mammalian cells [28]. Thus, its ability to
mitigate  the  glycated  albumin-induced  TNF-α  release
indicates  the  importance  of  tyrosine  kinase  activity  in
mediating this inflammatory response. Consistent with this
hypothesis, tyrosine phosphorylation was measured in retinal
microglia  cells  after  glycated  albumin  treatment  in  the
presence/absence  of  genistein.  Microglial  recognition  of
glycated albumin induced an early and significant increase in
tyrosine phosphorylation which was reduced by genistein.
Because glycated albumin receptors structures and functions
remain to be clarified and no consensus tyrosine kinase motif
has  been  identified,  the  use  of  genistein,  broad-spectrum
tyrosine kinase inhibitor, opens the door for future work to
characterize which tyrosine kinase is involved after glycated
albumin receptor activation.
Besides  genistein’s  ability  to  inhibit  tyrosine  kinase
activity, other reported effects might have contributed to our
finding  of  genistein-anti-inflammatory  effect,  such  as
possession of antioxidant properties [29]. Emerging evidence
indicates that glycated albumin induced NADPH oxidase-
dependent ROS formation [30] that might subsequently alter
the  activity  of  tyrosine  phosphatase  which  normally
antagonize tyrosine kinase activity [31]. With this reduction
of antagonistic phosphatase activity, expression of tyrosine
kinase activity is unchecked, resulting in accumulation of
phosphyorylated  tyrosine  residues.  Therefore,  genistein's
ability  to  reduce  tyrosine  phosphorylation  could  also  be
explained  in  part  by  blockade  of  tyrosine  phosphatase
inactivation  via  its  antioxidant  activity.  Furthermore,
alterations in the activity of transcription factors involved in
the inflammation such as NF-κB has been reported to be an
important component of NADPH oxidase-dependent redox
signaling [32]. NF-κB is a pleiotropic regulator of many pro-
inflammatory cytokines that has been found to be activated by
a variety of stimuli, including diabetic stress [33,34]. These
findings, together with the observations that genistein inhibits
NF-κB activation in several cell types under stress conditions
[35-37]  suggest  that  the  ability  of  genistein  to  attenuate
glycated  albumin-induced  TNF-α  release  could  also  be
explained in part by blockade of NF-κB activation.
Previous studies demonstrated that MAPK activation is
necessary  for  NF-κB  activation,  induction  of  target  gene
expression, and secretion of proinflammatory cytokines from
immune cells [38,39]. In agreement, our study identified a
signaling  cascade  in  retinal  microglia  in  which  glycated
albumin  binds  its  receptor,  leading  to  phosphorylation  of
MAPKs, causing secretion of TNF-α. Furthermore, genistein
in our study had an appreciable inhibitory effect on glycated
albumin-induced  ERK/P38  phosphorylation  demonstrating
the  involvement  of  tyrosine  kinase  as  a  critical  upstream
signaling event in glycated albumin-mediated ERK and p38
MAPKs activation. Our results are not in agreement with the
finding  that  genistein  increases  the  activity  of  P38  and
inactivates ERK in immortalized human mammary epithelial
cells [40]. The cell-specific differences and the type of the
stimulator may contribute to these differences in response to
genistein. As the ERK pathway is most closely associated with
activation  of  tyrosine  kinase  receptors  [41],  blockade  of
glycated  albumin-induced  tyrosine  phosphorylation  by
genistein is consistent with its inhibition of ERK activation.
Genistein  similarly  prevented  P38  activation  by  glycated
albumin,  suggesting  that  in  retinal  microglia  the  glycated
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2040albumin  receptor  signaling  cascade  directly,  or  perhaps
indirectly, via ROS it generates, leads to p38 phosphorylation.
Collectively, the experiments in this study provide new
insights into the mechanisms of the anti-inflammatory effects
of  genistein,  demonstrating  that  genistein  decreases  the
expression of proinflammatory cytokines in retina of STZ-
injected  rats  and  decreases  microglial  activation,  thus
affording an anti-inflammatory effect. We also demonstrated
that as a tyrosine kinase inhibitor, genistein mitigates glycated
albumin-induced  TNF-α  release  from  activated  microglia
through ERK and p38 MAPKs-dependent mechanisms. In
conclusion,  these  data  provide  preclinical  evidence  that
genistein  might  be  a  promising  innovative  agent  in  the
treatment  of  the  diabetes-induced  retinal  inflammation.
Additionally,  our  data  present  new  thoughts  as  to  how
compounds similar to genistein, which possess tyrosine kinase
inhibitory  activity,  may  suppress  retinal  complications
associated with diabetes.
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